Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Aspacytarabine

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Biosight Launches a Phase 1/2 Trial of Aspacytarabine with Venetoclax
    Biosight Launches a Phase 1/2 Trial of Aspacytarabine with Venetoclax

    22 Nov 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/biosight-launches-a-phase-12-clinical-trial-of-aspacytarabine-in-combination-with-venetoclax-for-first-line-aml-induction-therapy-followed-by-aspacytarabine-consolidation-301685067.html

    PRNEWSWIRE
    22 Nov 2022
    Share Share
    Biosight Granted ODD from FDA for Aspacytarabine for Myelodysplastic Syndromes
    Biosight Granted ODD from FDA for Aspacytarabine for Myelodysplastic Syndromes

    01 Aug 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/biosight-granted-orphan-drug-designation-from-the-fda-for-aspacytarabine-for-the-treatment-of-myelodysplastic-syndromes-301596832.html

    PRNEWSWIRE
    01 Aug 2022
    Share Share
    Biosight Shows Final Primary Endpoint Data from Phase 2b Study of BST-236 in AML
    Biosight Shows Final Primary Endpoint Data from Phase 2b Study of BST-236 in AML

    06 Jan 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/01/06/2362832/0/en/Biosight-Reports-Final-Primary-Endpoint-Data-from-Phase-2b-Study-of-Aspacytarabine-BST-236-for-First-Line-Acute-Myeloid-Leukemia-Therapy.html

    GLOBENEWSWIRE
    06 Jan 2022
    Share Share
    Biosight Initiates Phase 2 Clinical Trial of Aspacytarabine for MDS and AML
    Biosight Initiates Phase 2 Clinical Trial of Aspacytarabine for MDS and AML

    12 Nov 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/11/12/2333405/0/en/Biosight-Announces-Initiation-of-Phase-2-Clinical-Trial-of-Aspacytarabine-for-MDS-and-AML.html

    GLOBENEWSWIRE
    12 Nov 2021
    Share Share
    Biosight Announces Initiation of Phase 2 Clinical Trial of Aspacytarabine
    Biosight Announces Initiation of Phase 2 Clinical Trial of Aspacytarabine

    16 Aug 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/08/16/2281034/0/en/Biosight-Announces-Initiation-of-Investigator-Sponsored-Phase-2-Clinical-Trial-of-Aspacytarabine-for-Relapsed-Refractory-AML-and-MDS-with-the-Groupe-Francophone-des-My%C3%A9lodysplasies.html

    GLOBENEWSWIRE
    16 Aug 2021
    Share Share
    Advaxis and Biosight Announce Entry into Definitive Merger Agreement
    Advaxis and Biosight Announce Entry into Definitive Merger Agreement

    06 Jul 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/07/06/2258015/0/en/Advaxis-and-Biosight-Announce-Entry-into-Definitive-Merger-Agreement.html

    GLOBENEWSWIRE
    06 Jul 2021
    Share Share